Kera Capital Partners Inc. Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kera Capital Partners Inc. acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,336 shares of the specialty pharmaceutical company's stock, valued at approximately $288,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Itau Unibanco Holding S.A. bought a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock worth $46,000 after purchasing an additional 121 shares during the period. Venturi Wealth Management LLC lifted its holdings in Jazz Pharmaceuticals by 577.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock worth $92,000 after buying an additional 704 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Jazz Pharmaceuticals by 56.7% in the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company's stock worth $119,000 after acquiring an additional 350 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Needham & Company LLC reiterated a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Piper Sandler reiterated an "overweight" rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Morgan Stanley raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $177.00.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $1.44 during midday trading on Friday, reaching $121.18. 388,542 shares of the company's stock traded hands, compared to its average volume of 538,909. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The company has a market cap of $7.33 billion, a price-to-earnings ratio of 17.07, a P/E/G ratio of 0.88 and a beta of 0.56. The stock has a 50 day moving average of $122.78 and a 200 day moving average of $114.75.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company's stock, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,253 shares of company stock worth $1,001,434. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.